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Preventing and/or reducing neuronal loss is still an unaddressed target and 
a major challenge in MS treatment. Although current and still experimental 
therapies may deal relatively well with neuroinflammation, substantially 
reducing relapse rate and number, neurodegeneration is still beyond an effective 
treatment. It is well established that neurons, devoid of their protective, 
insulating myelin sheath, are increasingly prone to degeneration resulting 
from either excitotoxicity [1], [2], oxidative stress [3], [4], reactive oxygen/
nitrogen species [5], [6] or a direct cytotoxic attack [7]–[9]. Hence, attempts 
to rapidly restore myelin appear as a sensible strategy for the prevention of 
neuronal loss in MS. One potential approach involves the transplantation of 
exogenous, remyelinating cells. Indeed, transplantation of various cell types 
with remyelination capacity has already proven to be beneficial in multiple 
MS animal models (e.g. see chapter 2). Grafted oligodendrocyte precursor 
cells (OPCs), neural stem cells (NSCs, in situ differentiating into functional 
oligodendrocytes), olfactory ensheathing cells (OECs) or Schwann cells have 
been shown to actively remyelinate denuded axons significantly contributing 
to neuroprotection [10]–[12]. Interestingly, some of these cell types appear to 
exert an additional neuroprotective function by the secretion of various potent 
anti‑inflammatory and neurotrophic factors [13]–[18]. Yet, the major problem 
with these initial myelin regeneration attempts was the allogenic nature of 
the grafted cells that urged the need for immunosuppression. The solution 
for the latter came with the development of induced pluripotency. Since 2006, 
scientists possess the knowledge that allows reprogramming of fully specialized 
somatic cells into a naive, pluripotent state [19]. These reprogrammed cells, 
called induced pluripotent stem cells (iPSCs), share the properties of embry‑
onic stem cells (ESCs), including the most prominent ones, i.e. the ability 
to endlessly self renew and the capacity for unrestrained differentiation. 
Consequently, generation of iPSCs from human somatic cells provided the 
means for the production of patient‑derived (autologous) specialised cell types 
for cell replacement purposes, virtually opening new horizons for regenerative 
medicine [20]–[24]. In this thesis we intended to evaluate the potential of iPSCs 
as a novel source of oligodendrocyte precursors for a myelin restorative (and so 
neuroprotective) therapy for MS.
In chapter 1, we introduced the multifaceted nature of MS. This chapter 
did not intend to provide a thorough exposition about the disease course and 
pathology (which can be found in various excellent reviews [25]–[29]), but 
rather focused on recent, sometimes controversial findings and hypotheses 
related to disease initiation mechanisms and MS susceptibility. In that respect, 
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the identification of the MS‑relevant function of potassium channel KIR4.1 [30], 
of which polymorphisms were found in genome wide association studies (GWAS) 
to be an MS risk factor, revealed the importance and usefulness of large‑scale 
genomic screens. It is very likely that more relevant MS‑susceptibility loci will be 
identified in future studies, provided the recruitment of large cohorts of various 
types of MS patients. It would be especially interesting to examine large cohorts 
of primary progressive MS (PPMS) patients, since there is increasing evidence 
that this form of MS may be considered the pure “genuine” version of the disease, 
as proposed in the “inside‑out” hypothesis of MS development [31]. If this model 
of MS is valid, the data of former GWAS focusing mainly on RRMS could have 
been easily confounded by the dominating (but secondary) event, namely an ex‑
cessive auto‑immune response and neuroinflammation [32]. It may be therefore 
worthwhile to concentrate on PPMS GWAS in the future in order to detect ad‑
ditional non‑inflammation related loci, potentially relevant for MS initiation [33]. 
In addition, the most widely used animal model for MS, experimental autoim‑
mune encephalomyelitis (EAE), may no longer be considered the most ap‑
propriate one to mimic MS in all aspects, but only the albeit important secondary 
aspect of MS disease pathology, i.e. aberrant, excessive autoimmune reactivity. 
Increased attention needs to be also paid to the, so far rather neglected, role 
of the epigenome in MS pathogenesis. A recent study already reported subtle, 
but genome‑wide differences in DNA methylation patterns between pathology‑
free brain regions derived from MS samples and those from control samples [34]. 
Importantly, the methylation status of some genes clearly corresponded with 
the level of their expression: hypermethylated BCL2L2 and NDGR1 (both 
genes associated with oligodendrocyte survival) were found to be expressed at 
significantly  lower levels, while hypomethylated LGMN and CTS2 (genes related 
to proteolytic processing) were expressed at significantly higher levels in MS CNS 
tissue compared to controls [34]. The fact that such alterations were described in 
presumed disease unaffected brain regions (with no visible signs of inflammation), 
might be another argument in favour of the “inside‑out” MS model, pointing 
towards an intrinsic dysregulation of myelin/oligodendrocyte homeostasis 
as being the primary event in disease development. Apart from differences in 
DNA methylation status, aberrant operation of other epigenetic components 
such as microRNAs (miRNAs) or histone deacetylases (HDACs) was found to 
be associated with MS. For instance, increased expression of mir‑155 was linked 
to defective blood brain barrier (BBB) function [35], to the promotion of Th1 
and Th17 T‑cell polarization [36] and to impaired neurosteroid synthesis [37], 
all of which can severely influence disease worsening. Histone deacetylation, on 
the other hand, constitutes (among others) an important mechanism regulating 
myelin production [38]–[40]. In conclusion, the perception of MS is dramatically 


























changing in recent years as new knowledge is being acquired. It is most likely 
that in the near future novel genetic, epigenetic and environmental factors 
contributing to MS disease development and progression will be identified, and 
some of them may become valid therapeutical targets.
We also addressed the remyelination process and its failure in MS in chapter 1. 
Since the general consensus states that the inability of remyelination in PPMS 
results from the impairment of the differentiation of endogenous myelinating cells, 
the actual roadblocks for OPC differentiation need to be identified, potentially 
leading to new targets for remyelination‑enhancing therapies [41]–[43]. As 
yet, the use of exogenous cell transplantation may be the only feasible approach to 
induce myelin restoration. Out of several engraftable cell types with a direct or 
indirect remyelination capability, NSCs and OPCs must be considered the most 
promising ones in terms of clinical applicability in the foreseeable future. Firstly, 
in contrast to for instance MSCs, NSCs/OPCs are of neural origin, which might 
facilitate their adaptation and acceptance in the CNS environment after grafting. 
Secondly, exposed to appropriate homing, chemotactic signals, NSCs/OPCs show 
a remarkable migration capacity, a property that is highly relevant in view of 
the multifocal distribution of MS lesions. And thirdly, in addition to their actual 
remyelination capacity, NSCs/OPCs were shown to possess an indirect neuro‑
protective and anti‑inflammatory competence through the secretion of a wide 
range of factors. In our opinion, the most favourable source for engraftable NSCs/
OPCs are iPSCs because of their high intrinsic proliferation potential, enabling 
the generation of high cell numbers required for transplantation, and the unique 
possibility to generate patient‑derived (so autologous) cell grafts. Chapter 1 was 
concluded by an introduction to the iPSC technology.
Chapter 2 summarised the use of exogenous human oligodendrocytes in 
(re)myelination research. It started with an outline of the process of normal 
human oligodendrogenesis, which is particularly relevant since most of the 
stem cell differentiation protocols intend to accurately recapitulate normal 
(in-vivo) oligodendrocyte development. Subsequently, we described and evalu‑ 
ated the potential sources for transplantable human OPCs that include cells 
isolated directly from human tissue, ESCs and iPSCs; the possibility to directly 
convert human somatic cells into OPCs, without an intermediate pluripotent 
stem cell stage, was also addressed. For each of these potential OPC sources, 
advantages and drawbacks were clearly pointed out. We provided an overview 
of the studies in which transplantation of exogenous OPCs was tested as strategy 
for de novo myelin formation or remyelination. In the vast majority of the 
listed experiments, application of exogenous OPCs resulted in a substantial 
improvement of the experimental conditions. However, without negating the 
beneficial impact of myelinating cell transplantation, the question arose whether 
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the experimental animal models used are clinically relevant. For instance, in 
most of spinal cord injury (SCI)‑driven demyelination models, cell grafting was 
performed within a couple of days after trauma induction, an approach that can 
not be used in the clinical situation (especially in case of auto‑logous iPSC‑derived 
cell transplantation). The neonate shiverer mouse model, representing congenital 
dysmyelination, is often used to show the efficacy of myelination by grafted 
exogenous cells, but this model clearly does not mimic focal demyelination as 
occurring in MS. The commonly used EAE model for MS might imitate autoimmune 
activity induced demyelination, but does not include neurodegeneration 
and oligodendrocyte loss as a primary event as proposed in the “inside‑out” 
concept of MS. It is obvious that new, more clinically relevant demyelination 
animal models need to be developed in line with the new insights in MS. 
The major goal of the experimental part of this thesis was to evaluate the 
potential and feasibility of iPSC‑derived OPC transplantation as MS therapy. 
In chapter 3, we began with the generation of mouse iPSCs using retroviral delivery 
of so‑called “Yamanaka factors” (Oct4, Sox2, Klf4 and cMyc) into mouse embryonic 
fibroblasts (MEFs). Successful establishment of truly pluripotent iPSC lines was 
confirmed by their typical “ESC‑like” gene expression profile, their multilineage 
differentiation potential in-vitro and ultimately by the teratoma formation 
assay. After verifying the quality of the generated iPSCs, we continued with 
directed differentiation experiments. Eventually, the multistage differentiation 
protocol that we established enabled the derivation of MBP/RIP double‑positive 
oligodendrocytes with an efficiency of about 18%. Most importantly, however, 
these iPSC‑derived oligodendrocytes were shown to produce mature myelin 
in-vitro as well as in-vivo upon transplantation into cuprizone‑demyelinated 
mouse brain. Our study on oligodendrocyte differentiation from iPSCs was one 
of the pioneering works in the field and the second one (after Tsuji et al. [44]) 
to demonstrate that cells derived from iPSCs are indeed capable of extensive 
myelin formation. As such, it provided an important proof of concept that iPSCs 
might constitute a valid alternative to other cellular platforms (like ESCs or CNS‑
isolated NSCs) in terms of the generation of clinically‑relevant myelinating cells 
for regenerative purposes. Still, if OPC grafting is intended to become a clinical 
reality, a number of relevant issues yet need to be solved. One of the prominent 
one is the low survival of transplanted cells. Our study showed that only ~20% of 
transplanted OPCs survived the initial weeks in-vivo and presumably, the actual 
number of surviving (i.e. functionally engrafted) cells will further decline in time. 
Thus, either significant improvement in grafting procedures or measures aiming 
at enhancing cell viability would be highly desirable. Some studies demonstrated 
that introduction of certain genes (e.g. Olig2 [45], [46], SOD1 [47], [48], BDNF [49], 
Bcl‑XL [50], BBL‑2 [51], CD44 [52]) into cells prior to transplantation, can great‑ 


























ly enhance their survival and lesion homing in-vivo. It seems feasible that 
increased OPCs survival during the most critical period of transplantation, i.e. 
immediately after injection, can be achieved by the transient modification of cell 
characteristics, e.g. by overexpression of pro‑survival or anti‑apoptotic genes.
Such a genetic manipulation approach, aiming at modifying another crucial 
aspect of OPC physiology, cell migration, constituted the focus of the following 
chapter of this thesis. Although OPCs posses a considerable migratory potential, 
it appears insufficient to reach demyelinated CNS areas distant from the injection 
site (see chapter 3). Similarly, incapability of endogenous OPCs to replenish demye‑ 
linated brain areas is also observed in MS [53]. In chapter 4 we set out to test 
whether overexpression of PSA‑NCAM in iPSC‑derived OPCs would result in an 
enhanced migratory capacity, as was demonstrated in previous studies in NSCs [54] 
and Schwann cells [55], [56]. We successfully generated an iPSC‑derived NSC 
line that stably overexpressed sialyl transferase X (STX), an enzyme involved in 
transferring polysialic acid residues onto the neural cell adhesion molecule. These 
PSA‑NCAM overexpressing NSCs were subsequently differentiated into OPCs 
according to our previously established protocol (chapter 3). We showed that 
PSA‑NCAM immunoreactivity persisted in OPCs upon this initial differentiation 
step and that PSA‑NCAM overexpression did not hamper the ability of the iPSC‑
derived OPCs to maturate into functional, myelin‑forming oligodendrocytes. 
Importantly, PSA‑NCAM expression was rapidly downregulated as soon as OPCs 
further proceeded with their differentiation towards mature oligodendrocytes. 
This downregulation is crucial as presence of PSA‑NCAM is generally recognised 
as one of the major obstacles for myelination [57], [58]. Whether PSA‑NCAM 
downregulation is the consequence of orchestrated, maturation‑depended 
DNA‑methylation of the promoter of the STX gene, or controlled by another 
epigenetic mechanism, remains to be elucidated. In a standard “wound‑healing” 
assay, we showed that the PSA‑NCAM‑overexpressing OPCs were able to migrate 
significantly faster than control OPCs. Ultimately, we transplanted PSA‑NCAM 
overexpressing OPCs into the demyelinated corpus callosum of cuprizone‑fed 
mice and demonstrated that these genetically‑modified iPSC‑derived OPCs were 
capable to migrate significantly further from the injection site than unmodified 
control OPCs. These findings are particularly relevant for the potential clinical 
application of autologous iPSC‑derived OPCs in MS patients, since such grafted 
OPCs have to travel considerably larger distances, to multiple sites of lesion and 
demyelination, in comparison to the present, relatively simple, experimental 
animal model. Obviously, before described genetic improvement approach could 
be feasible for clinical application, a safe nonviral method of gene delivery need 
to be established including the strict control of the expression of the transfected 
STX gene. 
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In chapter 5, we continued with exploring the potential use of human iPSCs 
as source for (autologous) remyelinating oligodendrocytes. We generated fully 
characterized human iPSC cell lines and started to explore possibilities for their 
directed differentiation. We became one of the first who succeeded to establish an 
elaborate multi‑stage procedure for the efficient in-vitro differentiation of human 
iPSCs into OPCs. In our differentiation procedure we accurately mimicked the 
different steps of normal in-vivo development of human oligodendrocytes, also 
reflected in the period of time (>120 days) required to obtain fully functional 
OPCs. The authenticity of these human iPSC‑derived OPCs was confirmed by 
the sequential expression of appropriate protein markers for each of the stages 
of differentiation. Co‑culturing of the human iPSC‑derived OPCs with rat DRG 
axons resulted in robust oligodendrocyte maturation and extensive myelination. 
In two mouse MS models, we tested the survival, distribution and functionality 
of the human iPSC‑derived OPCs after transplantation. In cuprizone‑fed mice, 
an animal model mimicking MS‑related demyelination events, the vast majority 
of stereotactically injected human iPSC‑derived OPCs indeed developed into 
mature functional oligodendrocytes that successfully remyelinated denuded 
axons in the corpus callosum. Intraventricular injection of the human iPSC‑
derived OPCs in the EAE mouse model for MS, imitating autoimmune‑associated 
inflammatory aspects of MS, resulted in a significant reduction of disease 
symptoms. However, the alleviation of symptoms could not be ascribed to an overt 
remyelination activity of the transplanted OPCs, since their actual homing into 
sites of lesions appear to be still limited. The beneficial effect of the human iPSC‑
derived OPCs seemed to be provided by their production of a broad panel of im‑
munomodulatory, anti‑inflammatory and neurotrophic factors. In fact, numerous 
studies clearly point towards secretome of OPCs and NSCs playing a pivotal role in 
ameliorating disease symptoms in MS mouse models [14], [15], [46], [59]–[61]. 
The crucial, recently‑identified, OPC/NSC‑produced factors include among 
others TGF‑β [62] and LIF [16], [63].
Our studies in the mouse models for MS clearly showed that transplantation of 
(autologous) human iPSC‑derived OPCs may have a promising therapeutic appli‑
cation for MS patients. However, before any step can be taken towards  potential 
clinical application, further research is required on a variety of issues related to 
mode of administration, cell distribution and migration, ultimate cell fate, safety, 
etc. The use of small nonhuman primates, in particular the EAE marmoset model, 
which is considered the animal model that most closely mimics MS in human, 
may provide a suitable approach for such studies [64]. In chapter 6 we reported 
a first small‑scale, short‑term (7 days) pilot study on the implantation of human 
iPSC‑derived OPCs in the marmoset EAE model, merely addressing practical 
aspects of the OPC transplantation procedure and establishing the initial fate of 


























intrathecally grafted cells.  In this short study, we found that only occasionally 
injected iPSC‑derived OPCs managed to invade the brain parenchyma close to the 
injection site, whereas (as yet) none of them reached a lesion site. These findings 
seem to be in accordance to previous studies by Pluchino et al, who intrathecally 
injected human NSCs in EAE marmosets [14]. The beneficial effects on the EAE 
disease score they found were ascribed to immunomodulatory factors produced 
by the implanted NSCs that accumulated and persisted in perivascular brain areas, 
distant from the actual lesion sites. Our pilot study only confirmed the feasibility 
and safety of human iPSC‑derived OPC transplantation in marmoset EAE model 
(no short‑term adverse effects; no signs of teratoma formation); it provided the 
first promising results concerning the survival of human iPSC‑derived OPC after 
transplantation. Long‑term follow‑up studies will have to establish and optimize 
their survival and migration towards lesioned areas in order to optimally profit 
from the dual mode of action of the autologous human iPSC‑derived OPC, 
i.e. via the production of immunomodulatory and neuroprotective factors and 
via remyelination, determining the most adequate way to reduce disease scores. 
Depending on the outcome of these studies, initiation of a first clinical trial in MS 
patients can be considered. 
The discovery of induced pluripotency in 2006 has opened new horizons for 
regenerative medicine. With the appearance of iPSCs, the scientific and medical 
world got an alternative to ESCs for an ample source of patient‑derived (so 
autologous) specialised cell types, suitable for transplantation purposes and as 
a unique tool for disease modelling. Nevertheless, the initial euphoric reception 
of the new technology was somewhat tempered by reports indicating iPSC 
immunogenicity [65] (soon after denied by others [66], [67]) and differentiation 
problems due to incomplete cell reprogramming or preservation of epigenetic 
memory of the parental cells [68]–[70]; additionally, the methods used to generate 
iPSCs did not meet current clinical safety standards (i.e. the use of integrating virus 
and oncogenes for cell reprogramming). However, as the technology evolved, safe, 
integration‑free cell reprogramming strategies were implemented (e.g. [71]–[74]). 
Also, iPSC differentiation issues were revealed to be marginal, provided proper 
cell selection and adequately long in-vitro culturing erasing epigenetic memory 
[75]–[77]. Currently, scientists are able to produce high quality iPSCs suitable for 
trans‑plantation purposes as well as “disease in a dish” studies. As an example, 
hiPSC were recently used to model Pelizaeus‑Merzbacher Disease (PMD) – 
a rare leuko‑dystrophy caused by mutation of PLP1 gene [78]. Utilising oligoden‑
drocytes differentiated from hiPSCs of PMD patients, scientists managed to 
identify the increased susceptibility to endoplasmic reticulum (ER) stress as 
a main con‑tributor to the disease pathology. Provided the correction of disease‑
causing mutation, such hiPSC‑derived oligodendrocytes could conceivably be 
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also used as autologous transplants, possibly having more profound therapeutical 
effect than previously used allogenic NSCs [79].
In this thesis we examined the potential of iPSC technology for MS treatment. 
We provided evidence that transplantation of iPSC‑derived OPCs might eventually 
turn into a valid, effective therapeutical strategy. We believe that this approach 
will be especially beneficial for patients suffering from progressive forms of 
MS, for which no treatment is currently available. It may also prove useful for 
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